Results

Total Results: 2,080 records

Showing results for "drug".

381. Arthritis and Nontraumatic Joint Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/arthritis_hi_impact.pdf
     January 01, 2014 - Ann estimated 750,000 gout patients initiate uric acid-lowering drug therapy in the U.S. annually. … The drug is a genetically engineered form of recombinant porcine urate oxidase, an enzyme not found …  Key Expert Comments: Overall, experts thought that the drug might address the unmet need for a … Nat Rev Drug Discov 2009 Sep;8(9):688. PMID: 19721439 79. Helms S, Darbishire PL. … Positive phase III results for benlysta as lupus drug. Immunotherapy 2009 Sep;1(5):729. 85.

382. Urinary-Incontinence-Treatment Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/urinary-incontinence-treatment_executive.pdf
     April 01, 2012 - The drug needed to be given to eight older patients to achieve more than a 50 percent reduction in … Observational economic drug evaluations29,30 have demonstrated greater absolute rates of treatment … We concluded that there was a low risk of bias in the drug studies. … and nonpharmacological treatment modalities are superior to mono-drug therapy. … Drug Saf. 2001;24(9):703-13. PMID 11522122. 25. Wang PS, Levin R, Zhao SZ, et al.

383. Topic Brief on Mental Health Treatments in Pregnancy (pdf file)
     effectivehealthcare.ahrq.gov/system/files/docs/topic-brief-disposition-mental-health-pregnancy_0.pdf
     June 01, 2021 - antidepressants from preconception through delivery, compared to women with depression but without drug … However, drug levels were not an outcome of interest, and it was unclear how many of the 56 included … One RCT plans to compare a drug to a behavioral intervention for pregnant women with depression, and … Can drug effects explain the recent temporal increase in atonic postpartum haemorrhage? … Does the nomination represent a health care drug, intervention, device, technology, or health care

384. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1512.pdf
     December 01, 2015 - Food and Drug Administration (FDA) in the first half of 2016. … Afrezza is also listed as a tier 5 drug in some state Medicare drug plan formularies, which is the … Food and Drug Administration (FDA); 2012 Aug 3 [accessed 2012 Jun 18]. [2 p]. … Food and Drug Administration (FDA); 2014 Jun 27 [accessed 2015 Jan 23]. [5 p]. … Food and Drug Administration (FDA); 2014 Jun 30 [accessed 2015 Feb 09]. [5 p].

385. Disposition of Comments Report for Biologic and Nonbiologic Systemic Agents and Phottherapy for Treatment of Chronic Plaque Psoriasis (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/psoriasis-chronic_disposition-comments.pdf
     November 27, 2012 - Food and Drug Administration (FDA) can be included as per AHRQ. … Alefacept is no longer available; Astellas pulled the drug from the market in December 2011. … Although alefacept was voluntarily withdrawn from the market by the manufacturer this year, the drug … For inclusion/exclusion criteria, were data obtained from drug manufacturers? … Food and Drug Administration (FDA) for psoriasis treatment.”

386. #06 Developmental Delays ADHD, and Autism (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/06_devdelays_potential_high_impact_2012-12-10.pdf
     January 01, 2012 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug … This drug is being investigated for off-label use.

387. Data-Points-6-Tables1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/data-points-6-tables1.pdf
     January 01, 2009 - 1 Number of Beneficiaries With at Least One Part A, B, or D Drug Claim for a Biologic of Interest, … Continuously Enrolled Medicare Parts A and B Fee-for-Service (FFS) Population, by Class of Drug and … Biologics of Interest Among Continuously Enrolled Medicare Parts A and B FFS Population, by Class of Drug … 79.12 77.58 73.12 6 Demographic Breakdown of Beneficiaries With at Least One Part A, B, or D Drug … for a Biologic of Interest, Continuously Enrolled Medicare Parts A and B FFS Population, by Class of Drug

388. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1406.pdf
     September 26, 2014 - The drug-device combination has been approved in Europe. … Food and Drug Administration (FDA). … Food and Drug Administration (FDA); 2012 Nov 9. 63 p. … Food and Drug Administration (FDA). … Autoimmune Drug Focus; 2012 Oct 22. 1 p. 56.

389. Report of a Pilot Project: Rapid Cost Analyses of Selected Potential High-Impact Intervention Reports | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/horizon-scan/research-2015
     October 01, 2015 - Report of a Pilot Project: Rapid Cost Analyses of Selected Potential High-Impact Intervention Reports Research Report October 1, 2015 Download Main Document PDF 404.8 KB This report is available in PDF (405 kB) only. People using assistive technology may not be able to fully access information in this…

390. Effectiveness of Isosorbide Dinitrate and Hydralazine in Racial/Ethnic Subgroups With Heart Failure | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/congestive-heart-failure-medicines/research
     March 31, 2010 - ACEIs in patients with heart failure (HF) and left ventricular systolic dysfunction established this drug … outcome than those not receiving the drug. … group must survive until drug therapy is initiated, while patients in the control group are at risk … Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology … Pharmacoepidemiol Drug Saf 1998;7(4):275-280. 24. Suissa S.

391. Changing Patterns of Medication Use in Patients With Rheumatoid Arthritis in a Medicaid Population | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/rheumatoid-arthritis-medicine-1/research
     March 30, 2009 - used to identify adults with both a diagnosis of RA and at least one disease modifying anti-rheumatic drug … Register, other investigators reported that 18% of patients who initially met ACR criteria for RA were in drug-free … Trends in prescription drug expenditures by Medicaid enrollees. … A Blue Report on High Prescription Drug Use in Tennessee and its Consequences. Blue Series.

392. Appendix-D-Surveillance-Report-1 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/appendix-d-surveillance-report-1.xlsx
     September 30, 2015 - the trial did not indicate clear differences between treatments for pain, functioning, depression, or drug … Excluded patients with history of psychosis Substance use: Excluded patients with history of illicit drug … months followup Inclusion: Insured patients ≥65 years with osteoarthritis and continuous medical and drug … applicable; NR = not reported; NRS = numeric rating scale; NSAID = non-steroidal anti-inflammatory drug … ; OAT = opioid agonist therapy; OR = odds ratio; OUD = opioid use disorder; PDMP = prescription drug

393. App-D-Opioid-Chronic-Pain-Surveill-Report-1 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveill-report-1.xlsx
     September 30, 2015 - the trial did not indicate clear differences between treatments for pain, functioning, depression, or drug … Excluded patients with history of psychosis Substance use: Excluded patients with history of illicit drug … months followup Inclusion: Insured patients ≥65 years with osteoarthritis and continuous medical and drug … applicable; NR = not reported; NRS = numeric rating scale; NSAID = non-steroidal anti-inflammatory drug … ; OAT = opioid agonist therapy; OR = odds ratio; OUD = opioid use disorder; PDMP = prescription drug

394. Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/psoriasis-chronic/research-protocol
     September 27, 2011 - Food and Drug Administration (FDA) for psoriasis treatment. … FDA-approved biologic systemic and targeted therapies for plaque psoriasis Drug Name* Brand Name … (dosage form) Marketed By (Manufacturer) Target of Therapy FDA Indications * Drug name is the … FDA-approved nonbiologic systemic therapy for plaque psoriasis Drug Name* Brand Name (dosage form … Food and Drug Administration (FDA) will be included in this review (Tables 1–5).

395. Newer Medications for Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH) | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/prostatic-hyperplasia-medications/research-protocol
     April 24, 2015 - In the early 1990s, the Federal Drug Administration (FDA) approval of medications for BPH shifted LUTS … prostates with either agent are supported by systematic reviews. 10,13 Recently, newer drugs and other drug … Common medications used to treat LUTS associated with BPH Drug class Mechanism of action Medication … [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer … , drug manufacturer, device trade name, keyword] exp Product Surveillance, Postmarketing/ exp "Drug-Related

396. EHC Research Protocol (Amended): Treatments for Acute Episodic Migraine (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/migraine-treatments-research-amended-protocol.pdf
     January 09, 2020 - screening; (5) use of prescription drug monitoring program data; (6) availability of close follow-up … screening • Use of prescription drug monitoring program data • Availability of close follow-up • … And others KQ 2: Any oral, injection, infusion, topical nonopioid abortive drug, including: • … Drug Healthc Patient Saf. 2018;10:37-43. doi: 10.2147/DHPS.S151073. PMID: 29760569. 17. … Canadian Headache Society Guideline: acute drug therapy for migraine headache.

397. Maternal and Fetal Effects of Mental Health Treatments in Pregnant and Breastfeeding Women: A Systematic Review of Pharmacological Interventions (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/protocol-pharm-pregnant-women_0.pdf
     December 05, 2018 - Designing drug trials: considerations for pregnant women. … Food and Drug Administration. … Pharmacoepidemiol Drug Saf. 2013 Sep;22(9):1013-8. doi: 10.1002/pds.3495. PMID: 23893932. 30. … Allergies" OR "Drug Dependency" OR "drug effects" OR "Drug Sensitivity" OR harm* OR harms OR "Long … Therapy"[Mesh] OR "drug therapy"[Subheading] OR drug*[tiab] OR pharmacotherap*[tiab] OR pharmacologic

398. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/angina-heart-attack-treatments_research-protocol.pdf
     December 11, 2012 - metabolic conversion takes place via the hepatic cytochrome P-450 isoenzymes and is susceptible to drug … Adverse drug reactions (thrombocytopenia, allergic drug reaction) 2. … reactions (thrombocytopenia, allergic drug reaction), bleeding, and stent thrombosis None 14 … The safety outcomes will be framed to help identify adverse events, including adverse drug reactions … ™ Drug-eluting stent Abbott Vascular FDA approved DESyne™ novolimus- eluting stent Drug-eluting stent

399. #06 Developmental Delays ADHD, and Autism (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1312.pdf
     December 01, 2013 - Food and Drug Administration for inducing or augmenting labor and could be prescribed off label for … Food and Drug Administration (FDA). Oxytocin. [internet]. Silver Spring (MD): U.S. … Food and Drug Administration (FDA) [accessed 2013 Nov 18]. [2 p]. … Food and Drug Administration (FDA). Syntocinon. [internet]. Silver Spring (MD): U.S. … Food and Drug Administration (FDA) [accessed 2013 Nov 18]. [2 p].

400. S16 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s16.pdf
     October 01, 2007 - The regulatory framework for the drug approval process ensures a relatively predictable body of evidence … Neither these trials nor the drug approval process itself is designed to address all the needs of the … The evidence needed for drug approval addresses only the first of 3 questions that Archie Cochrane (the … Drug coverage—Which bisphosphonate drugs should be included on a drug fomulary? … Implications of pharmacogenomics for drug development and clinical practice.